- Publish date:
Side Effects of Cancer Treatment: Hyperpigmentation
by Dr. C.H. Weaver M.D. updated 11/2020
What is hyperpigmentation
Hyperpigmentation is a darkening of the skin. This darkening of the skin may be generalized (happen all over) or localized, causing blotchy skin.
What causes hyperpigmentation
Some chemotherapy agents can cause hyperpigmentation. The cause of this side effect is currently unknown but may involve direct toxicity, stimulation of melanocytes (cells in skin responsible for skin color) and/or inflammation. Hyperpigmentation often appears 2 to 3 weeks after chemotherapy treatment begins and goes away as new skin cells replace the dead cells at approximately 10 to 12 weeks after treatment is over. However, this darkening may occasionally be permanent.
Chemotherapy drugs associated with temporary hyperpigmentation include:
- Melphalan (Alkeran®)
- busulfan (Myleran®)
- cyclophosphamide (Cytoxan®)
- 5-fluorouacil (5-FU)
- doxorubicin (Adriamycin®)
- daunorubicin (DaunoXome®)
- bleomycin (Blenoxane®)
- BCNU (topical)
Update on Strategies to Improve Treatment for Triple Negative Breast Cancer
Keytruda, Tecentriq, and Sacituzumab Govitecan (IMMU-132) are promising TNBC treatment advances.
What are the symptoms of hyperpigmentation
Hyperpigmentation from chemotherapy drugs may be generalized or it may occur in specific areas, such as:
- Around the joints
- Under the nails
- In the mouth
- Along the vein used to infuse chemotherapy
- Under areas compressed by tape or dressings
- In the hair (horizontal bands in light haired individuals)
How is hyperpigmentation treated
At this time, there is no treatment for hyperpigmentation.
- Learn More About the Side Effects of Cancer Treatment
- For news on cancer updates, research and education subscribe to Cancer Connect's newsletters here.
- Connect with other patients and caregivers for information and support here.
